Oe, Yuki
Nomoto, Hiroshi
Cho, Kyu Yong
Yokozeki, Kei
Ono, Tsubasa
Miya, Aika
Kameda, Hiraku
Nakamura, Akinobu
Arimura, Yoshiaki
Atsumi, Tatsuya
Article History
Received: 4 February 2024
Accepted: 16 July 2024
First Online: 24 July 2024
Declarations
:
: The study was approved by the Institutional Clinical Research Review Board of Otaru General Hospital (Date of approval; 2022/5/10, Approval number; 04-001) and was conducted in accordance with the principles of the Declaration of Helsinki and its amendments. An opt-out informed consent approach was adopted for all the participants.
: Not applicable.
: YO has received honoraria for lectures from Novo Nordisk Pharma Ltd.. HN has received honoraria for lectures from Novo Nordisk Pharma Ltd. and Sumitomo Pharma Co., Ltd; and has obtained research support from Kowa Pharmaceutical Co.. AN has received honoraria for lectures from Mitsubishi Tanabe Pharma and has obtained research support from Kowa Co., Ltd. TA has received honoraria for lectures from GlaxoSmithKline plc., Eli Lilly Japan K.K., Nippon Boehringer Ingelheim Co., Ltd. Eisai Co. Ltd., AbbVie Inc., UCB Japan Co. Ltd., Novartis Pharma K.K., Pfizer Inc. Gilead Sciences, Inc., Daiichi Sankyo Co., Ltd., Gilead Sciences, Inc., Daiichi Sankyo Co., Ltd., AstraZeneca plc., Asahi Kasei Pharma Co., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd.; and research grants from Eli Lilly Japan K.K., AbbVie Inc., Bristol-Myers Squibb Co., Daiichi Sankyo Co., Ltd., Asahi Kasei Pharma Co., Eisai Co. Ltd., Chugai Pharmaceutical Co., Ltd., AstraZeneca plc., Novartis Pharma K.K., Pfizer Inc. and UCB Japan Co., Ltd.; and consultancy fees from GlaxoSmithKline plc., Eli Lilly Japan K.K., Nippon Boehringer Ingelheim Co., Ltd., Boehringer Ingelheim., Bristol-Myers Squibb Co., Amgen K.K., Novartis Pharma K.K., Otsuka Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Gilead Sciences, Inc. and Daiichi Sankyo Co., Ltd.. KYC, KY, TO, AM, HK, and YA have no conflicts of interest to declare.